This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: February 12, 2004
Last updated: January 10, 2011
Last verified: January 2011
The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of non-coronary artery bypass graft (CABG) major and minor bleeding.

Condition Intervention Phase
Percutaneous Coronary Intervention Drug: Enoxaparin sodium Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Percutaneous Coronary Intervention

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • the composite of non-CABG major and minor bleeding [ Time Frame: up to H48 after index PCI ]

Secondary Outcome Measures:
  • success rate of achieving ACT target range [ Time Frame: at the beginning and end of procedure ]

Estimated Enrollment: 3532
Study Start Date: January 2004
Study Completion Date: September 2005
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Male or non-pregnant female greater than or equal to 18 years of age
  • Undergoing non-emergent single or multiple sites/vessels PCI during the same procedure
  • PCI to be performed with a femoral approach


  • Known or suspected pregnancy in women of childbearing potential
  • Thrombolytic therapy within the previous 24 hours
  • Undergoing primary PCI for ongoing ST-segment elevation myocardial infarction (STEMI)
  • Undergoing rescue PCI after failed thrombolysis
  • Any other elective PCI scheduled within the following 30 days after the index PCI
  • Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, intracranial tumor or aneurysm; recent (<1 month) trauma or major surgery (including bypass surgery); active bleeding
  • Uncontrolled arterial hypertension
  • Recent (<48 hours) or planned spinal/epidural anesthesia or puncture
  • Impaired haemostasis: known International Normalized Ratio (INR) >1.5; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count <100,000/µL)
  • History of hypersensitivity or contraindication to heparin or LMWH
  • Treatment with oral anticoagulant therapy within 72 hours prior to inclusion or current need for vitamin-K antagonist therapy
  • Treatment with a direct thrombin inhibitor, low molecular weight heparin, or unfractionated heparin within the 24 hours preceding enrolment
  • Use of abciximab within the previous 7 days or, tirofiban, or eptifibatide within the past 12 hours of index PCI
  • Inability to give informed consent or high likelihood of being unavailable for follow-up
  • Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrollment in this trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00077844

Sponsors and Collaborators
Study Director: Luc Sagnard Sanofi
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00077844     History of Changes
Other Study ID Numbers: XRP4563_4001
EudraCT #: 2004-003743-44
Study First Received: February 12, 2004
Last Updated: January 10, 2011 processed this record on August 18, 2017